Epoxomicin
| Names | |
|---|---|
| IUPAC name
(2S,3S)-N-((2S,3R)-3-hydroxy-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxobutan-2-yl)-3-methyl-2-((2S,3S)-3-methyl-2-(N-methylacetamido)pentanamido)pentanamide
| |
| Other names
BU 4061T
| |
| Identifiers | |
CAS Number
|
|
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
InChI
| |
SMILES
| |
| Properties | |
Chemical formula
|
C28H50N4O7 |
| Molar mass | 554.729 g·mol−1 |
| Appearance | White solid |
| Solubility in DMSO | 10 mg/mL |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
| |
Epoxomicin is a naturally occurring selective proteasome inhibitor with anti-inflammatory activity.[2] It was originally discovered in 1992.[3] Injected, it can induce Parkinson's-like symptoms in rats.
Derivatives of epoxomicin include carfilzomib.
- ^ Epoxomicin, Santa Cruz Biotechnology
- ^ Meng, L; Mohan, R; Kwok, BH; Elofsson, M; Sin, N; Crews, CM (1999). "Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity". PNAS. 96 (18): 10403–10408. Bibcode:1999PNAS...9610403M. doi:10.1073/pnas.96.18.10403. PMC 17900. PMID 10468620.
- ^ Epoxomicin, Peptide Institute, Inc.